Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications association between tumor necrosis factor inhibitor tnfi therapy changes c reactive
… , Zhang Y, Tempest M, Pearson I , Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca … J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, …
PIE and Post-Approval AMCP Dossiers Image Pre-Approval Information Exchange (PIE) Materials Unapproved Medical Product Dossiers and Unapproved Use Dossiers An unapproved product dossier, or an unapproved use dossier, allows you to communicate key product …
… of clinicaltrials.gov (2013-2022) Mordin M , Castro C, Gnanasakthy A Transcript An article published in 2015 from a review of clinicaltrials.gov indicated that between 2007 and 2013, there was an increase in the number of …
… or coauthored more than 450 peer-reviewed scholarly publications. He is a former president of the Society for …
Using RTI Rarity™ to Support Clinical Trial Diversity Requirements Local Social Inequity Score Offers Precise Analysis of Social Risk Data The US Food and Drug Administration (FDA) recently released guidance that outlines specific diversity requirements …
… as propensity scores, when estimating risk measures of association. In addition, we assist researchers with …
… change in disease-related costs Estimating and presenting changes in annual budget impact and health outcomes …
… recommendations. To anticipate the potential for changes to the CDC’s ACIP recommendations ahead of a recent … attitudes, beliefs, and preferences for potential changes to pneumococcal disease immunization recommendations …
… pregnancy requirements and safety in rare disease and gene therapy. Here are the details. #314: Registries Aren’t Always … studies. #362: Assessing Safety in Rare Disease and Gene Therapy Wednesday, June 28 • 4:00pm - 5:00pm Chair: Alicia … bring new safety challenges. Specific to gene therapy for example, in addition to organ toxicities, there …
Meaningful Work From understanding the cost-effectiveness of treatments to helping reduce risks to patients to ensuring that patient preference is considered in the development of new therapies—we are passionate about what we do. Our scientists actively …